Presented at EASD, the analysis put Foundayo 17.2 mg ahead by 1.5% in weight loss and 0.3% in A1C at 52 weeks, though no head-to-head trial was run.
Recap by typeshit. Full story at Drug Topics.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Varney says analyses find these products often hold just 5% to 75% of the labeled dose, and some carry arsenic at up to 10 times safe levels.
STAT reports from a peptide medicine conference where stem cell entrepreneur Chuck Meeker predicted FDA roundtables before year end. The FDA declined to comment.
Loading…